专家简介
祁岩超 男, 1949年生, 汉族人,中共党员, 教授, 主任医师,硕士导师,国家突出贡献专家。
工作单位 广州医学院附属肿瘤医院生物工程研究室
通讯地址：广州市横枝岗路78号 邮编：510095
电 话：020-83595032-3087（0） E-Mail: YCQI@tom.com
教育背景:
1972-1975河南医科大学医疗系.学习。 1979-1982河南医科大学研究生班.攻读硕士。 1981-1981加拿大Yes生物技术公司专业研修
工作经历:
①、1975-1979河南叶县医院医师 ②、1982-1995河南省肿瘤医院副研究员 ③、1995-2001广州市肿瘤医院主任医师 ④、2002- 今 广州医学院附属肿瘤医院教授、主任医师
社会兼职：
世界科教文卫组织专家组成员；世界健康学会联合会常务理事；全国名医理事会副理事长；中华医学会科技奖评审委员；中国实用神经疾病杂志副主编；中国组织工程研究与临床康复杂志常务编委；中华现代内科学杂志常务编委；世界肿瘤杂志常务编委；美国中华医学与管理杂志编委；国家自然科学基金会评审专家；中国老年学会肿瘤专业委员会执行委员；广东省医疗卫生高级职称评审委员；中国医师网健康顾问委员会 主任委员； 广州抗癌协会生物治疗专业委员会 副主任委员；广州抗癌协会 理事。
学术成就：
从事肿瘤应用研究和肿瘤内科及生物治疗工作20余年，以中晚期肿瘤的体细胞生物治疗和细胞因子研究为专长。1985年以来共获科研成果9项，成果奖15项，1985年完成的“杂交细胞抑制肿瘤细胞恶性浸润的研究”获省科技进步三等奖。1989年主持省医科院“脏器细胞应用研究”获省医药卫生成果三等奖。1991年主持的“人胸腺素的制备研究”获省医药卫生成果二等奖, 省科技进步三等奖。1993年主持的“神经生长因子的制备和应用研究”获94雅加达中国医药卫生科技成就展览会金奖,广州市科技进步三等奖。1996年主持的省科委攻关课题“安吉复治疗老年性痴呆的研究”1998 年获省医药科技成果二等奖,解放军科技进步三等奖。2002年主持的“CEA阳性肿瘤特异性免疫的治疗方法”2006年获中国医院管理协会医疗新技术一等奖;1992年获“国家突出贡献专家”称号。著有《细胞生长因子基础和临床》等3部专著及译著1部，发表《脐血CD3AK细胞治疗恶性肿瘤的临床应用研究》等论文100余篇，其中国家级杂志30余篇，国际杂志6篇。三项成果: “CEA阳性肿瘤特异性免疫的治疗方法”申报了国家专利,“人胎胸腺素”和“神经生长因子”的研究获得国家专利。目前主要研究方向是利用CIK，DC细胞和CEA基因重组痘苗等现代生物技术个体化治疗恶性肿瘤的应用研究，并且在国内首家用CEA-rV基因痘苗治疗CEA阳性肿瘤病人的临床应用研究，取得了良好效果，填补了国内空白。
2001—2007年承担课题情况
2001年 荷CEA-瘤苗抗原的DC诱导特异性CTL应用研究 项目编号 2000-GK-10 广州医学院
2002年 CEA基因痘苗诱导特异性抗肿瘤免疫反应的研究 项目编号 2002C30305 广东省科技厅攻关项目
2003年 干细胞的体外培养及临床应用研究 项目编号 2003Z3-E0011 广州市科技局攻关项目
2004年 热证肺癌HSP70-PC对人肺癌细胞免疫的研究 项目编号 04010022 广东省自然科学基金
2004年 肿瘤患者术后预防复发的个体化综合治疗应用研究 项目编号 200421-11 广州市医药卫生科技项目（卫生局）
2005年 针刺合神经生长因子治疗脑性瘫痪的机理研究 项目编号5002028 广东省自然科学基金
2006年 荷CEA-rV的DC激活的CIK治疗CEA阳性肿瘤的实验研究 项目编号 2006B35502013 广东省科技厅攻关项目
2007年 针刺和神经生长因子治疗脑性瘫痪的基础研究 项目编号30740074 国家自然科学基金委员会
获奖情况:
1985年以来，获省、市、厅、局科研成果9项，成果奖16项
１. 恶性和正常细胞杂交细胞体外抑制恶性亲本细胞浸润的观察 1985年获河南省人民政府科技进步三等奖。
２. 人胎胸腺素的制备及生物活性测定 1991年获河南省政府科技进步三等奖。
３. 神经生长素的基础理论和临床应用研究2000年获广州市科技进步三等奖。
４. 神经生长因子在某些神经系统疾病中的临床应用观察 1999年获中国人民解放军科技进步三等奖。
５. 安吉复口服液 1998年获安徽省医药管理局科技进步二等奖。
６. 胎儿脏器细胞输注的实验和临床应用研究1993年获省卫生科技进步三等奖。
７. 神经生长因子项目 1994年获卫生部中国医药卫生科技成就金奖。
８. “CEA阳性肿瘤的特异免疫治疗方法” 2006年获中国医院协会第二届MTA医疗新技术成果一等奖
９. “CEA阳性肿瘤特异性免疫治疗的基础理论和临床应用研究” 2007年通过广东省科委的成果鉴定 科学成果证书登记号 GK08037
专利三项
１．神经生长因子的制备方法 专利号：ZL.93101062.4 授权日期 2000年3月17日，第一专利人
2. 胸腺素的制备方法 专利号：ＺＬ.101061.6 授权日期 1999年2月27日 第一专利人
3. 一种治疗和预防CEA阳性肿瘤的效应细胞的制备方法和应用 2007年申请了国家专利 专利公开号: CN 101037670A 第一专利人
2001年以来发表文章目录
1． 祁岩超.李峥.田培.陈汉奎: 脐血CD3细胞输注对肿瘤患者PBMC的 NK活性影响 肿瘤防治研究 2001;28(1):36
2． 祁岩超.杨波.赵鹏:树突状细胞在肿瘤免疫疗法中的现状与展望 肿瘤防治杂志 2002；9（5）（特）：434-436
3． YC. Qi .YD. Wang. XM. Zhang：Preparation and bioactivity assay of CD3AK cell from umbilical cord. The Chinese-German .Journal of Clinical Oncology 2002;1(3):172-174
4. Yanchao QI, Xinshuai Wang, Bo Yang et al: Preventive and therapeutic effects of CEA recombinant vaccinia virus on CEA positive tumor. Journal of Tumor Marker Oncology 2004;19(5):409-413
5.祁岩超,王远东,刘枫等: 神经生长因子对急性脑卒中的疗效观察 中国临床医药研究杂志 2002;71(5):6079-6080
6.祁岩超. 王得周. 杨波等: 脐血CD3AK细胞的制备、生物活性测定及临床应用初探 肿瘤防治研究 2004；31（7）：381-383
7.祁岩超. 王得周. 杨波等: 脐血CD3AK细胞治疗恶性肿瘤的临床应用研究 中国肿瘤临床2004；31（17）973-976
8.Qi Yanchao: Basic theory and clinical application research of nerve growth factor(NGF). Meridian 2004;11(2):91-94
9.祁岩超. 杨家启. 王新帅等：荷肿瘤抗原的DC细胞增强CD3AK细胞特异杀伤作用的研究 世界肿瘤杂志 2005；4（3）：173-176
10.祁岩超. 王新帅 杨波等：荷CEA—vV的DC增强CD3AK对CEA阳性肿瘤特异杀伤作用的研究 世界肿瘤杂志 2005；4（4）：245-249
11.祁岩超. 王新帅. 杨波等：CEA-vV增强CD3AK对CEA阳性肿瘤的特异杀伤作用的研究 中国肿瘤生物治疗杂志 2005；12（4）：292-294
12.祁岩超. 姜鸿南. 王远东等：脐血来源CIK细胞的体外扩增培养 世界肿瘤杂志 2006；5（1）：12-15
13.祁岩超. 刘振寰：小儿脑瘫的治疗现状与展望 中国实用神经疾病杂志 2006；9（1）：102-105
14.杨波. 祁岩超. 卢敏莹：人脐血来源的树突状细胞的体外培养扩增 实用癌症杂志 2003；19（2）117-120
15.李锦洲. 祁岩超. 罗超权：CEA重组痘苗病毒对实验性CEA阳性肝癌的预防和防治作用 郑州大学学报（医学版）2005；40（4）：667-669
16.张桂华. 潘东晓. 祁中浩. 史强. 祁岩超: 脐血CD3AK细胞治疗恶性肿瘤的观察与护理 中国实用护理杂志 2005；21（12）：1-3
17.祁岩超, 杨波, 卢敏莹, 等. 流式细胞术分析6类肿瘤患者外周血淋巴细绝对说数值的变化。癌症进展（增刊），2006，4（10）：86-88
18.Qi Yanchao, Wang Xingshua YangBo, et al. The study of special killing effect of CD3AK on anti-CEA-positive tumor enhanced by DC loaded with CEA-rV. The Chinise-German Journal of Clinical Oncology, 2006,5(6):1-4
19.刘振寰, 潘佩光,祁岩超,等.电针对新生鼠缺氧缺血脑组织神经细胞凋亡及神经生长蛋白表达的影响 中国临床康复 2006,10(23):114-118
20.杨家启,祁岩超,姜鸿南,等.荷CEA-rV的DC诱导的CIK对CEA阳性原代肿瘤细胞的特异杀伤作用. 中华肿瘤防治杂志 2007,14(14):1054-1058
22.祁岩超,刘振寰.神经生长因子的促智作用分析. 中国实用神经疾病杂志 2007,10(7):17-19
21.刘振寰,祁岩超,潘佩光,等,针刺合神经生长因子对脑瘫患儿脑功能代偿的影响.中国针灸 2007,27(8): 565-568
23.Qi Yanchao, Jian Hongnan, Yang Bo. Special killing effect of CIK induced by DC [oaded with CEA-rV on CEA-positive primary tumor cell. AACR Annual Meeting, April 2007. Los Angeles CA, #2740.
24.田慧, 祁岩超, 王远东,等.CEA-rV负荷树突状细胞与CIK细胞共培养后对裸鼠结肠癌移植瘤生长的抑制作用 实用预防医学 2007,14(5):1380-1383
25.祁岩超, 杨波,王新帅.CEA-rV防治CEA阳性肿瘤的实验和应用研究 癌症进展2008,6(增刊):110-115
26.姜鸿南,祁岩超. CIL细胞生物学特性及抗肿瘤作用的研究进展 世界肿瘤杂志 2008,7(1):52-55
English Resume
Name: YanChao QI Date of Birth: 1949 Man 
Affiliation: Biological Engineering Research Center, Tumor Hospital of Guangzhou Medical College
Address: 78 Hengzhigang street, Guangzhou,China
Postal Code: 510095 Tel: 020-83595032-3087（0）
E-Mail: YCQI@tom.com
Title:
National Professional of Outstanding Contribution, P.R. China
Guangzhou Medical College Professor
Tumor Hospital of Guangzhou Medical College Chief Physician
Tumor Hospital of Guangzhou Medical College Master's Tutor
Education:
1972----1975: Department of Medical Treatment of Henan Medical University MB
1979----1981: Henan Medical University Master of Medicine
1981----1981 Yes Biotech Laboratories Ltd. Canada Training
Experience of Research and Work:
1975----1979: Henan Ye County Hospital Doctor
1982----1995 Henan Provincial Tumor Hospita Associate Professor
1995----2001 Cancer Hospital in Guangzhou City Chief Physician
2002----Present time Guangzhou Tumor Hospital Chief Physician
Guangzhou Medical College Professor
Master of Medicine
Academic Achievements
Have been working in Application research of tumors, medical and biological treatment of cancer more than 20 years, Advanced to the tumor cells biological treatment and cytokines research. Since 1985, All of 9 scientific research achievements and 16 awards and prizes have been obtained. In 1985 the project about "hybrid cells curb the infiltration of malignant tumor cells" was rated as scientific and technological progress third Awards of HeNan Province. In 1989 the project about “the applied of research of organ cells’’ of the HeNan Provincial Academy of Medical Sciences was rated as the medical and health outcomes third Awards. In 1991 the project about “The preparation of People thymosin’’ was rated as the medical and health outcomes second Awards and Province scientific and technological progress third Awards. In the same year, the project about “The Preparation of nerve growth factor and applied research’’ got the Gold Award of the exhibition of Chinese medical and health science and technology achievements in Djakarta, and was rated as Guangzhou scientific and technological progress third Awards. In 1996 the project about “The research about treatment of Alzheimer's disease with JiFuAn’’ was rated as the Guangzhou medical and health scientific and technological outcomes third Awards and PLA's scientific and technological progress third place. In 2006 the project about “CEA positive tumor-specific immune therapy’’ got the new medical technology award of Chinese Hospital Management Association. In 1992 I Was awarded the title of “National Professional of Outstanding Contribution”. All three books had been published including << The basic and clinic of Cell growth factor >> and a Translation. All more than 100 papers had been published including "The clinical application of CD3AK cord blood cells to treat malignant tumors ", of which more than 30 papers on national journal, 6 papers on international Journal. At present, I got a total of three research results; the income of “CEA positive tumor-specific immune therapy’’ have been declared a national patent, the study of "Human fetal thymosin" and "nerve growth factor," have received national patent. At present, the main research direction is to apply modern biotechnology such as CIK, DC cells and CEA gene recombination vaccine to treat malignant tumors, and that is the first in the country develop clinical study to treat cancer patients of the CEA positive with CEA-rV vaccine, has been made good results, filled the gaps in the domestic.
Part-time jobs：
WHO |
Members of the expert group |
Federation of the World Health Institute |
Executive director |
Academy of Chinese and Western natural Medicine Sciences |
Academician |
Chinese Institute of Contemporary medical scientists |
Vice president |
The journal of Chinese practical nerve disease |
Deputy Editor-in-Chief |
The journal of Chinese modern medicine |
Managing Editor |
The journal of World tumor |
Managing Editor |
The American Journal of Chinese Medicine and Management |
Editor |
National Natural Science Fund Committee |
Accreditation experts |
Tumor Professional Committee of Chinese Association of Gerontology |
Executive Member |
Guangdong health Senior Title |
Accreditation experts |
China's Health Network physicians Advisory Board |
Chairman |
Biological Therapy Professional Committee of Guangzhou Anti-cancer Association |
Vice director |
Guangzhou Anti-cancer Association |
Director |
The projects during 2001-2006:
2001. The Applied study on the specific CTL induced by DC with CEA vaccine antigen. No.: 2000-GK-10 Guangzhou Medical College
2002. The study on specific anti-tumor immune response induced by CEA gene vaccine. No.: 2002C30305 The key project of Guangdong Provincial Science and Technology Office
2003. The culture in vitro and clinical application of the stem cells. No.: 2003Z3-E0011 The key project of the Guangzhou Technology Bureau
2004. The study on the effect of lung cancer HSP70-PC on human immunoreaction of lung cancer cell No.:04010022 Natural Science Foundation of Guangdong Province
2004 The application research to prevent recurrence of Cancer patients after the surgery with the individual comprehensive treatment. No.: 200421-11 The medical and health technology projects of Guangzhou City (Health Bureau)
2005. The mechanism of treating cerebral palsy with acupuncture and nerve growth factor No.: 5002028 Natural Science Foundation of Guangdong Province
2006. The experimental study on treatment of CEA-positive tumors with CIK actived by the DC with CEA-rV. No.: 2006B35502013 The key project of the Guangdong Provincial Science and Technology Office
2007. The basic research about treating of cerebral palsy with acupuncture and nerve growth factor No.: 30740074 National Natural Science Fund
Awards:
All of 9 scientific research achievements and 16 awards and prizes have been obtained since 1985. Some as follow:
1. The study on the hybrid cell of normal and malignant cell suppress malignant invading capacity of their parents malignant cells in vitro. The scientific and technological progress third Awards, HeNan province Government, 1989
2. The preparation and biological activity assay of human fetal thymus. The scientific and technological progress third awards, HeNan province, 1991
3. The study on the basic theory and clinical application of Nerve growth factor. The scientific and technological progress third Awards, Guangzhou city, 2000
4. The clinical observation of treating certain diseases of the nervous system with Nerve growth factor. The PLA's scientific and technological progress third Awards. 1999
5. The AnJiFu Oral liquid The scientific and technological progress second Awards, Pharmaceutical Administration Bureau of AnHui Province, 1998
6. Experimental and clinical research of the fetal organ cells infusion Health and science and technology progress third Awards, Henan province, 1993
7. The project of Nerve growth factor. The Gold Prize of Chinese medical and health science and technology achievements, the Ministry of Health, 1994
8. CEA positive tumor-specific immune therapy The first awards of new medical technology incomes in the Second MTA, Chinese Hospital Association, 2006
9. The basic theory and clinical study of CEA positive tumor-specific immune therapy The results were identified by the Guangdong Provincial Science and Technology Commission. The registration certificate of scientific results: GK08037
Patents: three items of national patents of China;
1. The preparation of nerve growth factor (NGF). Patent No.: ZL.93101062.4 Authorized date: 3-17-2000 The first Patent holders
2. The preparation of human fetal thymosin (THN). Patent No.: ＺＬ.101061.6 Authorized date: 2-27-1999 The first Patent holders
3. The preparation and application of effective cells that can treat and prevent the CEA positive tumor Patent No.: CN 101037670A The date of application: 2007 The first Patent holders
Papers Published since 2001:
1. YC.Qi, Zhen Li, Pei Tian, Hankui Chen. The influence of the infusion of umbilical cord blood CD3 cells on the activity of the NK cells of PBMC of tumor patients. Cancer Research on Prevention and Treatment. 2001; 28(1):36
2. YC. Qi et al. The progress and prospect on the role of Dendritic cells in cancer immunotherapy. The Journal of Cancer Prevention and Treatment. 2002；9（5）：434-436
3. YC. Qi .et al. Preparation and bioactivity assay of CD3AK cell from umbilical cord. The Chinese-German .Journal of Clinical Oncology. 2002;1(3):172-174
4. Yanchao QI, et al. The effects of CEA recombinant vaccinia virus on preventing and treating CEA positive tumor. Journal of Tumor Marker Oncology 2004; 19(5):409-413
5. YC. Qi et al. The effect of Nerve growth factor on treating acute stroke. The Chinese Journal of Clinical Medicine Research. 2002; 71(5):6079-6080
6. YC. Qi et al. The preparation, determination of biological activity and clinical application of cord blood CD3AK cells. Cancer Research on Prevention and Treatment. 2004; 31(7):381-383
7. YC.Qi et al. The clinical study on treating cancer with cord blood CD3AK cells. Journal of Clinical Oncology. 2004; 31(17): 973-976
8. Qi Yanchao: Basic theory and clinical application study on nerve growth factor(NGF). Meridian 2004; 11(2):91-94
9. YC.Qi et al. The study on the DC cell with tumor antigen can enhance the specific execution of CD3AK.The World Journal of Oncology. 2005; 4(3):173-176
10. YC.Qi et al. The study on the DC cell With CEA—vV can enhance the Specific execution of CD3AK to the CEA positive tumor. The World Journal of Oncology. 2005; 4(4): 245-249
11. YC.Qi et al. The study on CEA—vV can enhance the Specific execution of CD3AK to the CEA positive tumor. The Chinese Journal of Biological Treatment to Cancer. 2005; 12(4):292-294
12. YC.Qi et al. The culture in vitro of CIK cells from cord blood. The World Journal of Oncology. 2006; 5(1):12-15
13. YC.Qi et al. The progress and prospect in the treatment of cerebral palsy of Children. The Chinese Practical Journal of Nerve Disease. 2006;9(1):102-105
14. Bo Yang, YC.Qi et al. The culture in vitro of Dendritic cells from cord blood. Practical Journal of Cancer. 2003; 19(2):117-120
15. Jinzhou Li, YC.Qi et al. The effect of CEA recombinant vaccine virus on preventing and treating experimental CEA positive liver cancer. Journal of Zhengzhou University(Medical Edition). 2005; 40(4):667-669
16. GuiHua Zhang, DongXiao Pan, ZhongHao Qi, YanChao Qi. Observation and care after treatment of malignant tumors with cord blood CD3AK cells. Chinese Practical Nursing Journal. 2005; 21(12):1-3
17. YC.Qi et al. To analyses the changes of absolute value of lymphatic cells of six categories of cancer patients with FCM. Cancer Progress(Supplement). 2006; 4(10):86-88
18. Qi Yanchao, Wang Xingshua YangBo, et al. The study of special killing effect of CD3AK on anti-CEA-positive tumor enhanced by DC loaded with CEA-rV. The Chinise-German Journal of Clinical Oncology, 2006; 5(6):1-4
19. ZhenHuan Liu, PeiGuang Pan, YC.Qi et al. The effects of electro acupuncture on the apoptosis of hypoxic ischemic brain nerve cells and the expression of nerve growth protein of newborn mice. Chinese clinical rehabilitation. 2006; 10(23):114-118
20. JiaQi Yang, YC.Qi et al. The specific killing effect of CIK induced by DC loaded with CEA-rV on the CEA positive primary tumor cell. Chinese Journal of Cancer Prevention and Treatment. 2007, 14(14):1054-1058
21. YC.Qi et al. The effect of nerve growth factor on improving intelligence. Chinese Practical Journal of Nerve Disease. 2007; 10(7):17-19
22. ZhenHuan Liu, YC.Qi et al. The effects of Acupuncture and nerve growth factor on the brain compensatory function of children with cerebral palsy. Chinese Acupuncture. 2007, 27(8): 565-568
23 .Qi Yanchao, Jian Hongnan, Yang Bo. Special killing effect of CIK induced by DC loaded with CEA-rV on CEA-positive primary tumor cell. AACR Annual Meeting, April 2007. Los Angeles CA, #2740.
24. Hui Tian, YC.Qi et al. The co-culture of dendritic cells with CEA-rV and CIK cells inhibits the growth of transplanted colon cancer in nude mice. Practical Preventive Medicine. 2007, 14(5):1380-1383
25. YC.Qi et al. The experimental and applied study of CEA-rV in preventing and treating CEA positive tumors . Cancer progress(supplement). 2008,6:110-115
26 .HongNan Jiang, YC.Qi et al. The progress of CIL cells in biology and the effect of anti-tumor. The World Journal of Oncology. 2008, 7(1):52-55
